Hyperkalemia (see Hyperkalemia, [[Hyperkalemia]]): FDA-approved for this indication in 10/15
Hyperkalemia in the Setting of Renin-Angiotensin-Aldosterone System (RAAS) Inhibitors
Pharmacology
Non-Absorbable Potassium Binder: takes hours-days
Metabolism
xxxx
Administration
xxxx
Dose Adjustment
Hepatic:
Renal:
Adverse Effects
Other Adverse Effects
xxx
xxx
xxx
References
Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors. N Engl J Med. 2015 Jan 15;372(3):211-21. doi: 10.1056/NEJMoa1410853. Epub 2014 Nov 21. [MEDLINE]
